# A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Study · id `cardio:ct-nct06845202` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06845202](<https://clinicaltrials.gov/study/NCT06845202>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06845202

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 105 participants.

## Technical summary

Registry record NCT06845202. Randomized; triple masking; primary purpose treatment. Start 2025-03-03 (actual); primary completion 2027-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 105 participants (enrolled count; ClinicalTrials.gov record NCT06845202, source copy `cardio:ctgov-nct06845202-2026-11-16`, retrieved 2026-11-18)
- Started: 2025-03-03 (actual) (ClinicalTrials.gov record NCT06845202, source copy `cardio:ctgov-nct06845202-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2027-08-31 (anticipated) (ClinicalTrials.gov record NCT06845202, source copy `cardio:ctgov-nct06845202-2026-11-16`, retrieved 2026-11-18)
- Completion: 2027-08-31 (anticipated) (ClinicalTrials.gov record NCT06845202, source copy `cardio:ctgov-nct06845202-2026-11-16`, retrieved 2026-11-18)
- Countries: United States; Argentina; Canada; Chile; Germany; Poland (ClinicalTrials.gov record NCT06845202, source copy `cardio:ctgov-nct06845202-2026-11-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06845202-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
- Condition: Obese or Overweight Healthy Volunteers
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): ALN-4324
- Intervention (Drug): Placebo
- Lead sponsor: Alnylam Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Alnylam Pharmaceuticals (`cardio:org-alnylam-pharmaceuticals`)

## Provenance

Content hash: de06973b6a1fc846ea2ad74f465428c63a63b841be49d0323c26b2a924fb11ad
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
